References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492
- Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017;9(3):448. doi:https://doi.org/10.21037/jtd.2017.02.75
- Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harbor Perspectives in Medicine. 2015;5(4):a006098. doi:https://doi.org/10.1101/cshperspect.a006098
- Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H. Resveratrol nanoformulation for cancer prevention and therapy. Ann NY Acad Sci. 2015;1348(1):20–31. doi:https://doi.org/10.1111/nyas.12811
- Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(2):41–59. doi:https://doi.org/10.1159/000443404
- Amawi H, Ashby CR, Samuel T, Peraman R, Tiwari AK. Polyphenolic nutrients in cancer chemoprevention and metastasis: role of the epithelial-to-mesenchymal (EMT) pathway. Nutrients. 2017;9(8):911. doi:https://doi.org/10.3390/nu9080911
- Angeloni C, Maraldi T, Milenkovic D, Vauzour D. Dietary polyphenols and their effects on cell biochemistry and pathophysiology 2014. Oxid Med Cell Longevity. 2015;2015:1–2. doi:https://doi.org/10.1155/2015/782424
- Abbaszadeh H, Keikhaei B, Mottaghi S. A review of molecular mechanisms involved in anticancer and antiangiogenic effects of natural polyphenolic compounds. Phytother Res. 2019;33(8):2002–14. doi:https://doi.org/10.1002/ptr.6403
- Landete J. Plant and mammalian lignans: a review of source, intake, metabolism, intestinal bacteria and health. Food Res Int. 2012;46(1):410–24. doi:https://doi.org/10.1016/j.foodres.2011.12.023
- Marcotullio MC, Curini M, Becerra JX. An Ethnopharmacological, phytochemical and pharmacological review on lignans from Mexican Bursera spp. Molecules. 2018;23(8):1976. doi:https://doi.org/10.3390/molecules23081976
- Sainvitu P, Nott K, Richard G, Blecker C, Jérôme C, et al. Structure, properties and obtention routes of flaxseed lignan secoisolariciresinol, a review. BASE. 2012;16(1):115–24.
- Saleem M, Kim HJ, Ali MS, Lee YS. An update on bioactive plant lignans. Nat Prod Rep. 2005;22(6):696–716. doi:https://doi.org/10.1039/b514045p
- Teponno RB, Kusari S, Spiteller M. Recent advances in research on lignans and neolignans. Nat Prod Rep. 2016;33(9):1044–92. doi:https://doi.org/10.1039/c6np00021e
- Xin H, Kong Y, Wang Y, Zhou Y, Zhu Y, et al. Lignans extracted from Vitex negundo possess cytotoxic activity by G2/M phase cell cycle arrest and apoptosis induction. Phytomedicine. 2013;20(7):640–7. doi:https://doi.org/10.1016/j.phymed.2013.02.002
- Zanwar A, Hegde M, Bodhankar S. Cardioprotective effect of flax lignan concentrate and omega-3-fatty acid alone and in combination in ischemia/reperfusion injury in isolated rat heart. Atherosclerosis. 2014;235(2):e251. doi:https://doi.org/10.1016/j.atherosclerosis.2014.05.751
- Zanwar AA, Hegde MV, Rojatkar SR, Sonawane KB, Rajamohanan PR, Bodhankar SL. Isolation, characterization and antihyperlipidemic activity of secoisolariciresinol diglucoside in poloxamer-407-induced experimental hyperlipidemia. Pharm Biol. 2014;52(9):1094–103. doi:https://doi.org/10.3109/13880209.2013.877492
- De Silva SF, Alcorn J. Flaxseed lignans as important dietary polyphenols for cancer prevention and treatment: chemistry, pharmacokinetics, and molecular targets. Pharmaceuticals. 2019;12(2):68. doi:https://doi.org/10.3390/ph12020068
- Rodríguez-García C, Sánchez-Quesada C, Toledo E, Delgado-Rodríguez M, Gaforio JJ. Naturally lignan-rich foods: a dietary tool for health promotion?Molecules. 2019;24(5):917. doi:https://doi.org/10.3390/molecules24050917
- Liu Y, Cao W, Zhang B, Liu Y-q, Wang Z-y, et al. The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci Rep. 2013;3:3098. doi:https://doi.org/10.1038/srep03098
- Ong CP, Lee WL, Tang YQ, Yap WH. Honokiol: a review of its anticancer potential and mechanisms. Cancers. 2019;12(1):48. doi:https://doi.org/10.3390/cancers12010048
- Banik K, Ranaware AM, Deshpande V, Nalawade SP, Padmavathi G, et al. Honokiol for cancer therapeutics: a traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019;144:192–209. doi:https://doi.org/10.1016/j.phrs.2019.04.004
- Pusztai R, Abrantes M, Sherly J, Duarte N, Molnar J, et al. Antitumor-promoting activity of lignans: inhibition of human cytomegalovirus IE gene expression. Anticancer Res. 2010;30(2):451–4.
- Dai X, Yin C, Guo G, Zhang Y, Zhao C, et al. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3. Toxicol Appl Pharmacol. 2018;358:110–9. doi:https://doi.org/10.1016/j.taap.2018.09.005
- Luo J, Hu Y, Kong W, Yang M. Evaluation and structure-activity relationship analysis of a new series of arylnaphthalene lignans as potential anti-tumor agents. PLOS One. 2014;9(3):e93516. doi:https://doi.org/10.1371/journal.pone.0093516
- Lee Y-S, Choi S-S, Yonezawa T, Teruya T, Woo J-T, Kim HJ, Cha B-Y. Honokiol, magnolol, and a combination of both compounds improve glucose metabolism in high-fat diet-induced obese mice. Food Sci Biotechnol. 2015;24(4):1467–74. doi:https://doi.org/10.1007/s10068-015-0189-6
- Rauf A, Patel S, Imran M, Maalik A, Arshad MU, et al. Honokiol: an anticancer lignan. Biomed Pharmacother. 2018;107:555–62. doi:https://doi.org/10.1016/j.biopha.2018.08.054
- Shen J-L, Man K-M, Huang P-H, Chen W-C, Chen D-C, et al. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 2010;15(9):6452–65. doi:https://doi.org/10.3390/molecules15096452
- Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ Sci B. 2017;18(3):194–214. doi:https://doi.org/10.1631/jzus.B1600299
- Lee Y-J, Lee YM, Lee C-K, Jung JK, Han SB, et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011;130(2):157–76. doi:https://doi.org/10.1016/j.pharmthera.2011.01.010
- Sarrica A, Kirika N, Romeo M, Salmona M, Diomede L. Safety and toxicology of magnolol and honokiol. Planta Med. 2018;84(16):1151–64. doi:https://doi.org/10.1055/a-0642-1966
- Liu Z, Zhang X, Cui W, Zhang X, Li N, et al. Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats. Regul Toxicol Pharm. 2007;49(3):160–71. doi:https://doi.org/10.1016/j.yrtph.2007.06.006
- Li N, Song Y, Zhang W, Wang W, Chen J, et al. Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regul Toxicol Pharm. 2007;49(3):154–9. doi:https://doi.org/10.1016/j.yrtph.2007.06.005
- Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009;11(5):1139–48. doi:https://doi.org/10.1089/ars.2009.2440
- Cho Y-Y, Jeong H-U, Kim J-H, Lee HS. Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes. Drug Des Devel Ther. 2014;8:2137. doi:https://doi.org/10.2147/DDDT.S72305
- Yang C, Zhi X, Xu H. Advances on semisynthesis, total synthesis, and structure-activity relationships of honokiol and magnolol derivatives. Mini Rev Med Chem. 2016;16(5):404–26. doi:https://doi.org/10.2174/1389557516666151120115558
- Zhang J, Chen Z, Huang X, Shi W, Zhang R, et al. Insights on the multifunctional activities of magnolol. BioMed Res Int. 2019;2019:1–15. doi:https://doi.org/10.1155/2019/1847130
- Huang KJ, Kuo CH, Chen SH, Lin CY, Lee YR. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy. J Cell Mol Med. 2018;22(3):1894–908. doi:https://doi.org/10.1111/jcmm.13474
- Shen J, Ma H, Zhang T, Liu H, Yu L, et al. Magnolol inhibits the growth of non-small cell lung cancer via inhibiting microtubule polymerization. Cell Physiol Biochem. 2017;42(5):1789–801. doi:https://doi.org/10.1159/000479458
- Cheng Y-C, Hueng D-Y, Huang H-Y, Chen J-Y, Chen Y. Magnolol and honokiol exert a synergistic anti-tumor effect through autophagy and apoptosis in human glioblastomas. Oncotarget. 2016;7(20):29116. doi:https://doi.org/10.18632/oncotarget.8674
- Lee JS, Sul JY, Park JB, Lee MS, Cha EY, et al. Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway. Int J Mol Med. 2019;43(5):1969–78. doi:https://doi.org/10.3892/ijmm.2019.4122
- Songjang W, Jiraviriyakul A. Honokiol and magnolol induce apoptosis and cell cycle arrest in human ovarian cancer cells. PJ. 2019;11(5):1114–23. doi:https://doi.org/10.5530/pj.2019.11.174
- Tsai J-R, Chong I-W, Chen Y-H, Hwang J-J, Yin W-H, et al. Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells. Arch Pharmacal Res. 2014;37(4):548–57. doi:https://doi.org/10.1007/s12272-013-0232-1
- Green DR, Llambi F. Cell death signaling. Cold Spring Harb Perspect Biol. 2015;7(12):a006080. doi:https://doi.org/10.1101/cshperspect.a006080
- Popgeorgiev N, Jabbour L, Gillet G. Subcellular localization and dynamics of the Bcl-2 family of proteins. Front Cell Dev Biol. 2018;6:13. doi:https://doi.org/10.3389/fcell.2018.00013
- Gillies LA, Kuwana T. Apoptosis regulation at the mitochondrial outer membrane. J Cell Biochem. 2014;115(4):632–40. doi:https://doi.org/10.1002/jcb.24709
- Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63. doi:https://doi.org/10.1038/nrm3722
- Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018;25(1):104–13. doi:https://doi.org/10.1038/cdd.2017.169
- Hsiao C‑H, Yao C‑J, Lai G‑M, Lee L‑M, Whang‑Peng J, Shih P‑H. Honokiol induces apoptotic cell death by oxidative burst and mitochondrial hyperpolarization of bladder cancer cells. Exp Ther Med. 2019;17(5):4213–22. doi:https://doi.org/10.3892/etm.2019.7419
- Luo L-X, Li Y, Liu Z-Q, Fan X-X, Duan F-G, et al. Honokiol induces apoptosis, G1 arrest, and autophagy in KRAS mutant lung cancer cells. Front Pharmacol. 2017;8:199. doi:https://doi.org/10.3389/fphar.2017.00199
- Yan B, Peng Z-Y. Honokiol induces cell cycle arrest and apoptosis in human gastric carcinoma MGC-803 cell line. Int J Clin Exp Med. 2015;8(4):5454.
- Chang KH, Yan MD, Yao CJ, Lin PC, Lai GM. Honokiol‑induced apoptosis and autophagy in glioblastoma multiforme cells. Oncol Lett. 2013;6(5):1435–8. doi:https://doi.org/10.3892/ol.2013.1548
- Li M, Zhang F, Wang X, Wu X, Zhang B, et al. Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway. Cancer Sci. 2015;106(10):1341–50. doi:https://doi.org/10.1111/cas.12762
- Chen Y, Huang K, Ding X, Tang H, Xu Z. Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway. J Thorac Dis. 2019;11(7):3030. doi:https://doi.org/10.21037/jtd.2019.07.46
- Zhong W-B, Wang C-Y, Ho K-J, Lu F-J, Chang T-C, et al. Magnolol induces apoptosis in human leukemia cells via cytochrome c release and caspase activation. Anti-Cancer Drugs. 2003;14(3):211–7.
- Yang SE, Hsieh MT, Tsai TH, Hsu SL. Effector mechanism of magnolol‐induced apoptosis in human lung squamous carcinoma CH27 cells. Br J Pharmacol. 2003;138(1):193–201. doi:https://doi.org/10.1038/sj.bjp.0705024
- Wen H, Zhou S, Song J. Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells. Biochem Biophys Res Commun. 2019;508(4):1271–8. doi:https://doi.org/10.1016/j.bbrc.2018.12.087
- Park JB, Lee MS, Cha EY, Lee JS, Sul JY, et al. Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway. Biol Pharm Bull. 2012;35(9):1614–20. doi:https://doi.org/10.1248/bpb.b12-00352
- Wang Y-D, Sun X-J, Yang W-J, Li J, Yin J-J. Magnolol exerts anticancer activity in hepatocellular carcinoma cells through regulating endoplasmic reticulum stress-mediated apoptotic signaling. OncoTargets Ther. 2018;11:5219. doi:https://doi.org/10.2147/OTT.S168887
- Huang SH, Chen Y, Tung PY, Wu JC, Chen KH, et al. Mechanisms for the magnolol‐induced cell death of CGTH W‐2 thyroid carcinoma cells. J Cell Biochem. 2007;101(4):1011–22. doi:https://doi.org/10.1002/jcb.21100
- Tse AK-W, Wan C-K, Shen X-L, Yang M, Fong W-F. Honokiol inhibits TNF-α-stimulated NF-κB activation and NF-κB-regulated gene expression through suppression of IKK activation. Biochem Pharmacol. 2005;70(10):1443–57. doi:https://doi.org/10.1016/j.bcp.2005.08.011
- Xu H, Tang W, Du G, Kokudo N. Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis. Drug Discov Ther. 2011;5(5):202–10. doi:https://doi.org/10.5582/ddt.2011.v5.5.202
- You Q, Li M, Jiao G. Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells. Arch Pharmacal Res. 2009;32(12):1789–94. doi:https://doi.org/10.1007/s12272-009-2218-6
- Raja SM, Chen S, Yue P, Acker TM, Lefkove B, et al. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis. Mol Cancer Ther. 2008;7(7):2212–23. doi:https://doi.org/10.1158/1535-7163.MCT-07-2409
- Zhang Y, Ren X, Shi M, Jiang Z, Wang H, et al. Downregulation of STAT3 and activation of MAPK are involved in the induction of apoptosis by HNK in glioblastoma cell line U87. Oncol Rep. 2014;32(5):2038–46. doi:https://doi.org/10.3892/or.2014.3434
- Abdal Dayem A, Hossain M, Lee S, Kim K, Saha S, Yang G-M, Choi H, Cho S-G. The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles. IJMS. 2017;18(1):120. doi:https://doi.org/10.3390/ijms18010120
- Hafezi K, Hemmati AA, Abbaszadeh H, Valizadeh A, Makvandi M. Anticancer activity and molecular mechanisms of α‐conidendrin, a polyphenolic compound present in Taxus yunnanensis, on human breast cancer cell lines. Phytother Res. 2020;34(6):1397–408. doi:https://doi.org/10.1002/ptr.6613
- Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 2016;1863(12):2977–92. doi:https://doi.org/10.1016/j.bbamcr.2016.09.012
- Orrenius S, Gogvadze V, Zhivotovsky B. Calcium and mitochondria in the regulation of cell death. Biochem Biophys Res Commun. 2015;460(1):72–81. doi:https://doi.org/10.1016/j.bbrc.2015.01.137
- Huang K, Chen Y, Zhang R, Wu Y, Ma Y, Fang X, Shen S. Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis. 2018;9(2):1–17. doi:https://doi.org/10.1038/s41419-017-0166-5
- Zhou Y, Bi Y, Yang C, Yang J, Jiang Y, et al. Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway. Die Pharmazie. 2013;68(9):755–62.
- Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14(4):348.
- Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17(5):280. doi:https://doi.org/10.1038/nrm.2016.27
- Duronio RJ, Xiong Y. Signaling pathways that control cell proliferation. Cold Spring Harbor Perspect Biol. 2013;5(3):a008904. doi:https://doi.org/10.1101/cshperspect.a008904
- Law ME, Corsino PE, Narayan S, Law BK. Cyclin-dependent kinase inhibitors as anticancer therapeutics. Mol Pharmacol. 2015;88(5):846–52. doi:https://doi.org/10.1124/mol.115.099325
- Mikhail S, Albanese C, Pishvaian MJ. Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers. Am J Pathol. 2015;185(5):1185–97. doi:https://doi.org/10.1016/j.ajpath.2015.01.008
- Chen Y, Li H, Zhang W, Qi W, Lu C, et al. Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway. Toxicol Appl Pharmacol. 2020;387:114848. doi:https://doi.org/10.1016/j.taap.2019.114848
- Jeong JB, Hong SC, Jeong HJ, Koo JS. Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells. Int Immunopharmacol. 2011;11(10):1573–7. doi:https://doi.org/10.1016/j.intimp.2011.05.016
- Hahm E-R, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther. 2007;6(10):2686–95. doi:https://doi.org/10.1158/1535-7163.MCT-07-0217
- Vaid M, Sharma SD, Katiyar SK. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation. Carcinogenesis. 2010;31(11):2004–11. doi:https://doi.org/10.1093/carcin/bgq186
- McKeown BT, McDougall L, Catalli A, Hurta RA. Magnolol causes alterations in the cell cycle in androgen insensitive human prostate cancer cells in vitro by affecting expression of key cell cycle regulatory proteins. Nutr Cancer. 2014;66(7):1154–64. doi:https://doi.org/10.1080/01635581.2014.951736
- Chen L-C, Liu Y-C, Liang Y-C, Ho Y-S, Lee W-S. Magnolol inhibits human glioblastoma cell proliferation through upregulation of p21/Cip1. J Agric Food Chem. 2009;57(16):7331–7. doi:https://doi.org/10.1021/jf901477g
- Chilampalli C, Guillermo R, Zhang X, Kaushik RS, Young A, et al. Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action. BMC Cancer. 2011;11(1):456. doi:https://doi.org/10.1186/1471-2407-11-456
- Chun Y, Kim J. Autophagy: an essential degradation program for cellular homeostasis and life. Cells. 2018;7(12):278. doi:https://doi.org/10.3390/cells7120278
- Linder B, Kögel D. Autophagy in cancer cell death. Biology. 2019;8(4):82. doi:https://doi.org/10.3390/biology8040082
- Lu Z, Cao S, Zhou H, Hua L, Zhang S, Cao J. Mechanism of arctigenin-induced specific cytotoxicity against human hepatocellular carcinoma cell lines: Hep G2 and SMMC7721. PLOS One. 2015;10(5):e0125727. doi:https://doi.org/10.1371/journal.pone.0125727
- Yun CW, Lee SH. The roles of autophagy in cancer. IJMS. 2018;19(11):3466. doi:https://doi.org/10.3390/ijms19113466
- Yoshii SR, Mizushima N. Monitoring and measuring autophagy. IJMS. 2017;18(9):1865. doi:https://doi.org/10.3390/ijms18091865
- Bednarczyk M, Zmarzły N, Grabarek B, Mazurek U, Muc-Wierzgoń M. Genes involved in the regulation of different types of autophagy and their participation in cancer pathogenesis. Oncotarget. 2018;9(76):34413. doi:https://doi.org/10.18632/oncotarget.26126
- Su T, Li X, Yang M, Shao Q, Zhao Y, et al. Autophagy: an intracellular degradation pathway regulating plant survival and stress response. Front Plant Sci. 2020;11:164. doi:https://doi.org/10.3389/fpls.2020.00164
- Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132–41. doi:https://doi.org/10.1038/ncb2152
- Yang X, Yu D-D, Yan F, Jing Y-Y, Han Z-P, et al. The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci. 2015;5(1):14. doi:https://doi.org/10.1186/s13578-015-0005-2
- Bishop E, Bradshaw TD. Autophagy modulation: a prudent approach in cancer treatment?Cancer Chemother Pharmacol. 2018;82(6):913–22. doi:https://doi.org/10.1007/s00280-018-3669-6
- Hahm ER, Sakao K, Singh SV. Honokiol activates reactive oxygen species‐mediated cytoprotective autophagy in human prostate cancer cells. Prostate. 2014;74(12):1209–21. doi:https://doi.org/10.1002/pros.22837
- Lu C-H, Chen S-H, Chang Y-S, Liu Y-W, Wu J-Y, et al. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells. Pharmacol Res. 2017;115:288–98. doi:https://doi.org/10.1016/j.phrs.2016.11.038
- Li H-b, Yi X, Gao J-m, Ying X-x, Guan H-q, Li J-c. Magnolol-lnduced H460 cells deathvia autophagy but not apoptosis. Arch Pharm Res. 2007;30(12):1566–74. doi:https://doi.org/10.1007/BF02977326
- Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(4):34. doi:https://doi.org/10.3390/biomedicines5020034
- Abbaszadeh H, Ebrahimi SA, Akhavan MM. Antiangiogenic activity of xanthomicrol and calycopterin, two polymethoxylated hydroxyflavones in both in vitro and ex vivo models. Phytother Res. 2014;28(11):1661–70. doi:https://doi.org/10.1002/ptr.5179
- Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177–83. doi:https://doi.org/10.3109/14756366.2016.1161620
- Yoo SY, Kwon SM. Angiogenesis and its therapeutic opportunities. Mediators Inflamm. 2013;2013:1–11.doi:https://doi.org/10.1155/2013/127170
- Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. In: Madame Curie bioscience database [Internet]. Austin, TX: Landes Bioscience; 2013.
- Fallah A, Sadeghinia A, Kahroba H, Samadi A, Heidari HR, et al. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed Pharmacother. 2019;110:775–85. doi:https://doi.org/10.1016/j.biopha.2018.12.022
- Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. BioMed Res Int. 2015;2015: 1–13. doi:https://doi.org/10.1155/2015/549412
- Gu Y, Scheuer C, Feng D, Menger MD, Laschke MW. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin. Anti-Cancer Drugs. 2013;24(8):781–91. doi:https://doi.org/10.1097/CAD.0b013e328362fb84
- Jiang Z, Wu M, Miao J, Duan H, Zhang S, et al. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects. Int J Biochem Cell Biol. 2013;45(8):1710–9. doi:https://doi.org/10.1016/j.biocel.2013.04.030
- Kim KM, Kim NS, Kim J, Park J-S, Yi JM, et al. Magnolol suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting Ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. Nutr Cancer. 2013;65(8):1245–53. doi:https://doi.org/10.1080/01635581.2013.828082
- Wen J, Fu A, Chen LJ, Xie XJ, Yang GL, et al. Liposomal honokiol inhibits VEGF‐D‐induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009;124(11):2709–18. doi:https://doi.org/10.1002/ijc.24244
- Vavilala DT, Ponnaluri VC, Kanjilal D, Mukherji M. Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases. PLOS One. 2014;9(11):e113717. doi:https://doi.org/10.1371/journal.pone.0113717
- Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003;278(37):35501–7. doi:https://doi.org/10.1074/jbc.M302967200
- Chen M-C, Lee C-F, Huang W-H, Chou T-C. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells. Biochem Pharmacol. 2013;85(9):1278–87. doi:https://doi.org/10.1016/j.bcp.2013.02.009
- Pijuan J, Barceló C, Maiques O, Moreno DF, Sisó P, et al. In vitro cell migration, invasion and adhesion assays: from cell imaging to data analysis. Front Cell Dev Biol. 2019;7:107. doi:https://doi.org/10.3389/fcell.2019.00107
- Guan X. Cancer metastases: challenges and opportunities. Acta Pharmaceutica Sinica B. 2015;5(5):402–18. doi:https://doi.org/10.1016/j.apsb.2015.07.005
- Singh D, Srivastava SK, Chaudhuri TK, Upadhyay G. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci. 2015;2:19. doi:https://doi.org/10.3389/fmolb.2015.00019
- Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez VE, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9:1370. doi:https://doi.org/10.3389/fonc.2019.01370
- Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010;1803(1):3–19. doi:https://doi.org/10.1016/j.bbamcr.2009.07.004
- Guo Y, Liu N, Liu K, Gao M. Capsaicin inhibits the migration and invasion via the AMPK/NF-κB signaling pathway in esophagus sequamous cell carcinoma by decreasing matrix metalloproteinase-9 expression. Biosci Rep. 2019;39(8):1–12. doi:https://doi.org/10.1042/BSR20190819
- Xu F, Na L, Li Y, Chen L. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10(1):1–12. doi:https://doi.org/10.1186/s13578-020-00416-0
- Merchant N, Nagaraju GP, Rajitha B, Lammata S, Jella KK, et al. Matrix metalloproteinases: their functional role in lung cancer. Carcinogenesis. 2017;38(8):766–80. doi:https://doi.org/10.1093/carcin/bgx063
- Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015;2(1):26–34. doi:https://doi.org/10.1016/j.gendis.2014.12.002
- Son H, Moon A. Epithelial-mesenchymal transition and cell invasion. Toxicol Res. 2010;26(4):245–52. doi:https://doi.org/10.5487/TR.2010.26.4.245
- Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Koster J, Horlings HM, Meijer SL, van de Vijver MJ. Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Res Treat. 2019;174(3):649–59. doi:https://doi.org/10.1007/s10549-018-05089-5
- Loh C-Y, Chai J, Tang T, Wong W, Sethi G, Shanmugam M, Chong P, Looi C. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118. doi:https://doi.org/10.3390/cells8101118
- Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15(1):18. doi:https://doi.org/10.1186/s12943-016-0502-x
- Hwang E-S, Park K-K. Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci Biotechnol Biochem. 2010;74(5):961–7. doi:https://doi.org/10.1271/bbb.90785
- Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080 invasiveness in vitro. Planta Med. 2001;67(08):705–8. doi:https://doi.org/10.1055/s-2001-18345
- Chei S, Oh H-J, Song J-H, Seo Y-J, Lee K, et al. Magnolol suppresses TGF-β-induced epithelial-to-mesenchymal transition in human colorectal cancer cells. Front Oncol. 2019;9:752. doi:https://doi.org/10.3389/fonc.2019.00752
- Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019;13:1–26.doi:https://doi.org/10.3332/ecancer.2019.961
- Singh T, Katiyar SK. Honokiol inhibits non-small cell lung cancer cell migration by targeting PGE2-mediated activation of β-catenin signaling. PLOS One. 2013;8(4):e60749. doi:https://doi.org/10.1371/journal.pone.0060749
- Shen L, Zhang F, Huang R, Yan J, Shen B. Honokiol inhibits bladder cancer cell invasion through repressing SRC‑3 expression and epithelial‑mesenchymal transition. Oncol Lett. 2017;14(4):4294–300. doi:https://doi.org/10.3892/ol.2017.6665
- Lv X-q, Qiao X-r, Su L, Chen S-z. Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP. Acta Pharmacol Sin. 2016;37(12):1574–86. doi:https://doi.org/10.1038/aps.2016.81
- Wang W-d, Shang Y, Li Y, Chen S-z. Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation. Acta Pharmacol Sin. 2019;40(9):1219–27. doi:https://doi.org/10.1038/s41401-019-0240-x
- Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, et al. Honokiol inhibits epithelial–mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol. 2014;8(3):565–80. doi:https://doi.org/10.1016/j.molonc.2014.01.004
- Xia L, Tan S, Zhou Y, Lin J, Wang H, et al. Role of the NFκB-signaling pathway in cancer. OncoTargets Ther. 2018;11:2063. doi:https://doi.org/10.2147/OTT.S161109
- Avtanski D, Poretsky L. Phyto-polyphenols as potential inhibitors of breast cancer metastasis. Mol Med. 2018;24(1):29. doi:https://doi.org/10.1186/s10020-018-0032-7
- Aggarwal BB, Sung B. NF-κB in cancer: a matter of life and death. Cancer Discov. 2011;1(6):469–71. doi:https://doi.org/10.1158/2159-8290.CD-11-0260
- Basseres D, Baldwin A. Nuclear factor-κ B and inhibitor of κ B kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817–30. doi:https://doi.org/10.1038/sj.onc.1209942
- Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12(1):1–15. doi:https://doi.org/10.1186/1476-4598-12-86
- Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2(9):823–30. doi:https://doi.org/10.1158/2326-6066.CIR-14-0112
- Letícia de Castro Barbosa M, Alves da Conceicao R, Guerra Manssour Fraga A, Dias Camarinha B, Cristina de Carvalho Silva G, Gilcler Ferreira Lima A, Azevedo Cardoso E, de Oliveira Freitas Lione V. NF-κB signaling pathway inhibitors as anticancer drug candidates. ACAMC. 2017;17(4):483–90. doi:https://doi.org/10.2174/1871520616666160729112854
- Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, et al. Sesamin manifests chemopreventive effects through the suppression of NF-κB–regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 2010;8(5):751–61. doi:https://doi.org/10.1158/1541-7786.MCR-09-0565
- Maxwell T, Chun S-Y, Lee K-S, Kim S, Nam K-S. The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression. Int J Oncol. 2017;50(2):727–35. doi:https://doi.org/10.3892/ijo.2016.3825
- Yang B, Ni X, Chen L, Zhang H, Ren P, et al. Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma. Drug Deliv. 2017;24(1):660–9. doi:https://doi.org/10.1080/10717544.2017.1303854
- Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, Singh AP. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLOS One. 2011;6(6):e21573. doi:https://doi.org/10.1371/journal.pone.0021573
- Peng Q, Deng Z, Pan H, Gu L, Liu O, et al. Mitogen-activated protein kinase signaling pathway in oral cancer. Oncol Lett. 2018;15(2):1379–88.
- Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, et al. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007. doi:https://doi.org/10.3892/etm.2020.8454
- Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. IJMS. 2020;21(3):1102. doi:https://doi.org/10.3390/ijms21031102
- Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. IJMS. 2020;21(7):2346. doi:https://doi.org/10.3390/ijms21072346
- Yang J, Nie J, Ma X, Wei Y, Peng Y, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. doi:https://doi.org/10.1186/s12943-019-0954-x
- Hassan B, Akcakanat A, Holder AM. Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin. 2013;22(4):641–64. doi:https://doi.org/10.1016/j.soc.2013.06.008
- Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):165.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:https://doi.org/10.1016/j.cell.2011.02.013
- Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017;45:62–71. doi:https://doi.org/10.1016/j.ceb.2017.02.007
- Hillmann P, Fabbro D. PI3K/mTOR pathway inhibition: opportunities in oncology and rare genetic diseases. IJMS. 2019;20(22):5792. doi:https://doi.org/10.3390/ijms20225792
- Ortega MA, Fraile-Martínez O, Asúnsolo Á, Buján J, García-Honduvilla N, et al. Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR. J Oncol. 2020;2020:1–11. doi:https://doi.org/10.1155/2020/9258396
- Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 2009;106(6):1113–22. doi:https://doi.org/10.1002/jcb.22098
- Li Z, Dong H, Li M, Wu Y, Liu Y, et al. Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway. Mol Med Rep. 2018;17(2):2719–23.
- Lin C-J, Chen T-L, Tseng Y-Y, Wu G-J, Hsieh M-H, et al. Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway. Toxicol Appl Pharmacol. 2016;304:59–69. doi:https://doi.org/10.1016/j.taap.2016.05.018
- Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, et al. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol. 2008;591(1–3):43–51. doi:https://doi.org/10.1016/j.ejphar.2008.06.026
- Yeh P-S, Wang W, Chang Y-A, Lin C-J, Wang J-J, et al. Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration. Cancer Lett. 2016;370(1):66–77. doi:https://doi.org/10.1016/j.canlet.2015.08.030
- Chuang T-C, Hsu S-C, Cheng Y-T, Shao W-S, Wu K, et al. Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Lett. 2011;311(1):11–9. doi:https://doi.org/10.1016/j.canlet.2011.06.007
- Lin H-L, Cheng W-T, Chen L-C, Ho H-O, Lin S-Y, et al. Honokiol/magnolol-loaded self-assembling lecithin-based mixed polymeric micelles (lbMPMs) for improving solubility to enhance oral bioavailability. Int J Nanomed. 2021;16:651. doi:https://doi.org/10.2147/IJN.S290444
- Wang Y-J, Chien Y-C, Wu C-H, Liu D-M. Magnolol-loaded core–shell hydrogel nanoparticles: drug release, intracellular uptake, and controlled cytotoxicity for the inhibition of migration of vascular smooth muscle cells. Mol Pharmaceutics. 2011;8(6):2339–49. doi:https://doi.org/10.1021/mp200257y
- Wu W, Wang L, Wang L, Zu Y, Wang S, et al. Preparation of honokiol nanoparticles by liquid antisolvent precipitation technique, characterization, pharmacokinetics, and evaluation of inhibitory effect on HepG2 cells. Int J Nanomed. 2018;13:5469. doi:https://doi.org/10.2147/IJN.S178416